RS54693B1 - Sulfonamidi za prevenciju dijabetesa - Google Patents

Sulfonamidi za prevenciju dijabetesa

Info

Publication number
RS54693B1
RS54693B1 RS20160230A RSP20160230A RS54693B1 RS 54693 B1 RS54693 B1 RS 54693B1 RS 20160230 A RS20160230 A RS 20160230A RS P20160230 A RSP20160230 A RS P20160230A RS 54693 B1 RS54693 B1 RS 54693B1
Authority
RS
Serbia
Prior art keywords
diabetes
days
day
reparixin
stz
Prior art date
Application number
RS20160230A
Other languages
English (en)
Serbian (sr)
Inventor
Lorenzo Piemonti
Luisa Daffonchio
Marcello Allegretti
Original Assignee
Dompé Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompé Farmaceutici S.P.A. filed Critical Dompé Farmaceutici S.P.A.
Publication of RS54693B1 publication Critical patent/RS54693B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RS20160230A 2009-10-06 2010-10-06 Sulfonamidi za prevenciju dijabetesa RS54693B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09172365A EP2308485A1 (en) 2009-10-06 2009-10-06 Sulfonamides for the prevention of diabetes
PCT/EP2010/064920 WO2011042465A1 (en) 2009-10-06 2010-10-06 Sulfonamides for the prevention of diabetes

Publications (1)

Publication Number Publication Date
RS54693B1 true RS54693B1 (sr) 2016-08-31

Family

ID=41716341

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160230A RS54693B1 (sr) 2009-10-06 2010-10-06 Sulfonamidi za prevenciju dijabetesa

Country Status (24)

Country Link
US (2) US8846755B2 (enExample)
EP (2) EP2308485A1 (enExample)
JP (1) JP5745526B2 (enExample)
KR (1) KR101737656B1 (enExample)
CN (1) CN102639128B (enExample)
AU (1) AU2010305384B2 (enExample)
BR (1) BR112012007989B1 (enExample)
CA (1) CA2776021C (enExample)
CY (1) CY1117599T1 (enExample)
DK (1) DK2485724T3 (enExample)
EA (1) EA021788B1 (enExample)
ES (1) ES2570463T3 (enExample)
HR (1) HRP20160399T1 (enExample)
HU (1) HUE028132T2 (enExample)
IL (1) IL219038A (enExample)
ME (1) ME02385B (enExample)
MX (1) MX2012004087A (enExample)
NZ (1) NZ599171A (enExample)
PL (1) PL2485724T3 (enExample)
RS (1) RS54693B1 (enExample)
SI (1) SI2485724T1 (enExample)
SM (1) SMT201600126B (enExample)
WO (1) WO2011042465A1 (enExample)
ZA (1) ZA201202462B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP3281937A1 (en) 2016-08-09 2018-02-14 Dompé farmaceutici S.p.A. Sulfonamides as gpr40- and gpr120-agonists
CN117503933A (zh) * 2016-10-03 2024-02-06 儿童医疗中心公司 糖尿病肾病的预防和治疗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
ITMI20010206A1 (it) * 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
US20040242498A1 (en) * 2003-02-27 2004-12-02 Collins Tassie L. CXCR3 antagonists
CN1934077B (zh) 2004-03-23 2010-09-29 冬姆佩制药股份公司 2-苯基丙酸衍生物及含有它们的药物组合物
DE602004003673T2 (de) 2004-03-25 2007-10-04 Dompe' Pha.R.Ma S.P.A. Verwendung von N-(2-Aryl-propionyl)-sulfonamiden zur Behandlung von Rückenmarkverletzungen
KR20110014141A (ko) * 2008-03-20 2011-02-10 카롤러스 테라퓨틱스, 인코포레이티드 염증을 치료하는 방법
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes

Also Published As

Publication number Publication date
EP2485724A1 (en) 2012-08-15
SI2485724T1 (sl) 2018-12-31
NZ599171A (en) 2014-03-28
SMT201600126B (it) 2016-07-01
AU2010305384A1 (en) 2012-04-26
US20130059908A1 (en) 2013-03-07
DK2485724T3 (en) 2016-05-02
HK1174557A1 (en) 2013-06-14
US8846755B2 (en) 2014-09-30
HUE028132T2 (en) 2016-11-28
JP5745526B2 (ja) 2015-07-08
PL2485724T3 (pl) 2016-07-29
HRP20160399T1 (hr) 2016-05-20
IL219038A0 (en) 2012-06-28
BR112012007989B1 (pt) 2019-10-22
CN102639128B (zh) 2014-02-26
WO2011042465A1 (en) 2011-04-14
EA021788B1 (ru) 2015-08-31
EP2308485A1 (en) 2011-04-13
CA2776021A1 (en) 2011-04-14
KR20120083889A (ko) 2012-07-26
KR101737656B1 (ko) 2017-05-18
US9556115B2 (en) 2017-01-31
CN102639128A (zh) 2012-08-15
ME02385B (me) 2016-09-20
EA201270512A1 (ru) 2012-11-30
EP2485724B1 (en) 2016-02-10
MX2012004087A (es) 2012-08-23
US20150011639A1 (en) 2015-01-08
IL219038A (en) 2015-07-30
CY1117599T1 (el) 2017-04-26
CA2776021C (en) 2017-08-01
ES2570463T3 (es) 2016-05-18
JP2013506703A (ja) 2013-02-28
ZA201202462B (en) 2013-06-26
AU2010305384B2 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
JP2535119B2 (ja) インスリン依存性糖尿病の治療用医薬組成物
EP2579879B1 (en) Triazine derivatives for delaying the onset of type 1 diabetes
Shah et al. Persistent hyperinsulinaemic hypoglycaemia in infancy
KR20110016889A (ko) 디피피-4 저해약과 다른 당뇨병 치료약과의 병용 또는 조합으로 이루어지는 의약
US9556115B2 (en) Sulfonamides for the prevention of diabetes
Reznik Continuous subcutaneous insulin infusion (CSII) using an external insulin pump for the treatment of type 2 diabetes
RS53249B (sr) Inhibitori cxcr1/2 kao adjuvansi u transplantaciji pankreasnih ostrvaca
HK1174557B (en) Sulfonamides for the prevention of diabetes
CN104582701A (zh) 减轻体重的方法
Anderson Calcium-channel blocker overdose
CN114984005B (zh) 硫酸舒欣啶在制备抗肾功能衰竭药物中的应用
US20210100872A1 (en) Pharmacological Formulation Comprising Cyclo (HIS-PRO) As Effective Ingredient For Preventing Or Treating Diabetes Mellitus
Piot et al. Full neurological recovery after extreme hypoglycemia during intensive insulin therapy: a case report
Milaszkiewicz Diabetes mellitus and anesthesia: What is the problem?
CN109865128A (zh) 阿必鲁泰在治疗和预防糖尿病合并脑梗塞药物中的应用
Ripal et al. A Review of Nateglinide in the Management of Type 2 Diabetes
Liu et al. Management of glycemia in diabetic patients with diabetic kidney disease
EGGLESTON et al. Transcription of Pamel Meeting on Therapeutics
CN115844916A (zh) 酸枣仁皂甙a的制药用途
CN113509544A (zh) 一种具有降血糖作用的药物组合物
WO2025155160A1 (ko) 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 비만 예방 또는 치료용 약학적 조성물
PAKRASHI et al. A new method for the production of experimental diabetes in rabbits
Schulze et al. 7.6 Insulin therapy
Sear Glucose control: what benefit, what cost in surgical patients?
JP2009155303A (ja) 血糖値上昇抑制補助剤、血糖値上昇抑制剤および糖尿病治療剤